This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioProcess International Events
Menu
Cell, Gene and CAR-T Therapieskeyboard_arrow_right

Cell, Gene and CAR-T Therapies

keyboard_arrow_leftSearch & Filter
search
Cell, Gene and CAR-T Therapies
search
Showing 1 of 1 Streams
On Demand
Adherent Cell Manufacturing & Process Development
On Demand - Premium Only
Analytical Method Development and Validation – Building the Characterization Testing Foundation & Toolkit
On Demand - Premium Only
Augmenting Automated Analytics for Cell & Gene Therapy Manufacture
On Demand - Premium Only
Closed, automated and controlled upstream processing for iPSC-derived cell therapies
On Demand - Premium Only
Data Governance and Data Integrity as a framework during Process Development
On Demand - Premium Only
Fresh vs. Cryopreserved: Tightening up Supply Chains
On Demand - Premium Only
Manufacturing and quality control of cell therapies
On Demand - Premium Only
PANEL: COVID-19: Trailblazers in the CGT Industry
On Demand - Premium Only
Phase Appropriate Thinking – Microbiology and Contamination Control
On Demand - Premium Only
Process Development Considerations for Exosomes
On Demand - Premium Only
Product Dependent Cryopreservation Protocols
On Demand - Premium Only
Sourcing Appropriate Starting and Ancillary Materials for Manufacturing Cell and Gene Therapy Products
On Demand - Premium Only
Tracking from Donor to Patient
On Demand - Premium Only
Delivering on the Promise of Producing Cost-Effective, High-Quality Allogeneic Immune Cell Therapies
On Demand - Premium Only
Development of modern biologics and cell therapy products through global CMOs
On Demand - Premium Only
Implementation of “off the shelf” Closed Systems fit for every purpose
On Demand - Premium Only
Non-Gene Edited Approaches to Allogeneic CAR-T Cell Therapy
On Demand - Premium Only
Optimizing Viral Vector Production
On Demand - Premium Only
PANEL DISCUSSION: Partnering Solutions for Staffing and Recruitment Issues in the CGT Space
On Demand - Premium Only
PANEL DISCUSSION: Spinning out from Academia and Ensuring early stage success
On Demand - Premium Only
PANEL: Autologous Manufacturing – What will Autologous Manufacturing of the Future Look Like?
On Demand - Premium Only
PANEL: Investment in the CGT space: trends, technologies and early stage success
On Demand - Premium Only
PANEL: Reimbursement Models for Novel Therapies
On Demand - Premium Only
PANEL: Strategies and Challenges in Manufacturing and Commercialization
On Demand - Premium Only
Pathogen Safety Margins for Gene Therapy Manufacturing
On Demand - Premium Only
Scalable Manufacture Platform of Human iPS-NK Cells for Off-the-Shelf Cell Therapies
On Demand - Premium Only
Starting Material Standardization for Auto and Allo Cell Therapies
On Demand - Premium Only
The Case for rAAV Titration by HPLC
On Demand - Premium Only
The Potential CAR-NK
On Demand - Premium Only
TAC T-cells leverage the Natural TCR’s properties, Have an Improved Safety Profile Compared to CAR-T cells and are Efficacious in Solid Tumors
On Demand - Premium Only
Efficacy/Toxicity Linkage with CAR and T Cell Therapies
On Demand - Premium Only
Cytokine modulation of CAR-T cells to improve their safety and efficacy
On Demand - Premium Only
Overcoming Cell Therapy Limitations with Next Generation Approaches based on Natural Killer Cells
On Demand - Premium Only
Standardization & QC for Gene Editing
On Demand - Premium Only
Developing allogeneic CAR T-cells that lack host reactivity and can resist rejection to improve their safety and persistence
NextAnalytical & Quality
Filter
Streams
Topics
Choose Day